Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: A case-series meta-analysis of a gene-environment interaction

Cancer Epidemiology Biomarkers and Prevention

Volumn 9, Issue 5, 2000, Pages 461-467

  Marcus, Pamela M ^a   Hayes, Richard B ^a   Vineis, Paolo ⁱ   Garcia Closas, Montserrat ^a   Caporaso, Neil E ^a   Autrup, Herman ^b   Branch, Robert A ^c   Brockmöller, Jürgen ^d   Ishizaki, Takashi ^e   Karakaya, Ali Esat ^f   Ladero, Jose M ^g   Mommsen, Soren ^h   Okkels, Henrik ^b   Romkes, Marjorie ^c   Roots, Ivar ^d   Rothman, Nathaniel ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b AARHUS UNIVERSITY   (Denmark)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d HUMBOLDT UNIVERSITY   (Germany)

^e KUMAMOTO UNIVERSITY   (Japan)

^f GAZI UNIVERSITY   (Turkey)

^g UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^h RANDERS REGIONAL HOSPITAL   (Denmark)

ⁱ UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; AROMATIC AMINE;

ACETYLATION; ACETYLATOR PHENOTYPE; ARTICLE; BLADDER CANCER; CANCER RISK; CIGARETTE SMOKING; CLINICAL TRIAL; DATA BASE; DETOXIFICATION; DNA POLYMORPHISM; ENVIRONMENTAL FACTOR; EUROPE; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; SMOKING HABIT;

ACETYLATION; AGED; AGED, 80 AND OVER; ARYLAMINE N-ACETYLTRANSFERASE; CASE-CONTROL STUDIES; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; RISK FACTORS; SMOKING; URINARY BLADDER NEOPLASMS;

EID: 18844480807     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Silverman, D. T., Morrison, A. S., and Devesa, S. S. Bladder cancer. In: D. Schottenfeld, and J. F. Fraumeni, Jr., Cancer Epidemiology and Prevention, New York: Oxford University Press, 1996, pp. 1156-1179.
2. IARC. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans: Tobacco Smoking. Lyon, France: WHO, 1986.
3. Ross, R. K., Jones, P. A., and Yu, M. C. Bladder cancer epidemiology and pathogenesis. Semin. Oncol., 23: 536-545, 1996.
4. Lower, G. M., Nilsson, T., Nelson, C. E., Wolf, H., Gamsky, T. E., and Bryan, G. T. N-Acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. Environ. Health Perspect., 29: 71-79, 1979.
5. Brockmöller, J., Cascorbi, I., Kerb, R., and Roots, I. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferase M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res., 56: 3915-3925, 1996.
6. Dewan, A., Chattopadhyay, P., and Kulkarni, P. K. N-Acetyltransferase activity - a susceptibility factor in human bladder carcinogenesis. Indian J. Cancer, 32: 15-19, 1995.
7. Evans, D. A. P., Eze, L. C., and Whibley, E. J. The association of the slow acetylator phenotype with bladder cancer. J. Med. Genet., 20: 330-333, 1983.
8. Hanssen, H. P., Agarwal, D. P., Goedde, H. W., Bucher, H., Huland, H., Brachmann, W., and Ovenbeck, R. Association of N-acetyltransferase polymorphism and environmental factors with bladder carcinogenesis. Eur. Urol., 11: 263-266, 1985.
9. Horai, Y., Fujita, K., and Ishizaki, T. Genetically determined N-acetylation and oxidation capacities in Japanese patients with non-occupational urinary bladder cancer. Eur. J. Clin. Pharmacol., 37: 581-587, 1989.
10. Ishizu, S., Hashida, C., Hanaoka, T., Maeda, K., and Ohishi, Y. N-Acetyltransferase activity in the urine in Japanese subjects: comparison in healthy persons and bladder cancer patients. Jpn. J. Cancer Res., 86: 1179-1181, 1995.
11. Kaisary, A., Smith, P., Jaczq, E., McAllister, B., Wilkinson, G. R., Ray, W. A., and Branch, R. A. Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res., 47: 5488-5493, 1987.
12. Karakaya, A. E., Cok, I., Sardas, S., Gogus, O., and Sardas, O. S. N-Acetyltransferase phenotype of patients with bladder cancer. Hum. Toxicol., 5: 333-335, 1986.
13. Ladero, J. M., Kwok, C. K., Jara. C., Fernández, L., Silmi, A. M., Tapia, D., and Usón, A. C. Hepatic acetylator phenotype in bladder cancer patients. Ann. Clin. Res., 17: 96-99, 1985.
14. Lower, G. M., and Bryan, G. T. Etiology and carcinogenesis: natural systems approaches to causality and control. In: N. Javadpour (ed.), Principles and Management of Urologic Cancer, pp. 29-53. Baltimore: Williams and Wilkins, 1979.
15. Miller, M. E., and Cosgriff, J. M. Acetylator phenotype in human bladder cancer. J. Urol., 130: 65-66, 1983.
16. Mommsen, S., and Aagaard, J. Susceptibility in urinary bladder cancer: acetyltransferase phenotypes and related risk factors. Cancer Lett., 32: 199-205, 1986.
17. Okkels, H., Sigsgaard, T., Wolf, H., and Autrup, H. Arylamine N-Acetyltransferase 1 (NAT1), and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking. Cancer Epidemiol. Biomark. Prev., 6: 225-231, 1997.
18. Peluso, M., Airoldi, L., Armelle, M., Martone, T., Coda, R., Malaveille, C., Giacomelli, G., Terrone, C., Casetta, G., and Vineis, P. White blood cell DNA adducts, smoking, and NAT2 and GSTM1 genotypes in bladder cancer: a case-control study. Cancer Epidemiol. Biomark. Prev., 7: 341-346, 1998.
19. Risch, A., Wallace, D. M. A., Bathers, S., and Sim, E. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum. Mol. Genet., 4: 231-236, 1995.
20. Roots, I., Drakoulis, N., Brockmöller, J., Janicke, I., Cuprunov, M., and Ritter, J. Hydroxylation and acetylation phenotypes as genetic risk factors in certain malignancies. In: R. Kato, R. W. Estabrook, and M. N. Cayen (eds.), Xenobiotic Metabolism and Disposition, pp. 499-506. London: Taylor and Francis, 1989.
21. Su, H. J., Guo, Y. L., Lai, M. D., Huang, J. D., Cheng, Y., and Christiani, D. C. The NAT2* slow acetylator genotype is associated with bladder cancer in Taiwanese, but not in the Black Foot Disease endemic area population. Pharmacogenetics, 8: 187-190, 1998.
22. Taylor, J. A., Umbach, D. M., Stephens, E., Castranio, T., Paulson, D., Robertson, C., Mohler, J. L., and Bell, D. A. The role of N-acetylation polymorphisms in smoking-associated bladder cancer: evidence of a gene-gene-exposure three-way interaction. Cancer Res., 58: 3603-3610, 1998.
23. Woodhouse, K. W., Adams, P. C., Clothier, A., Mucklow, J. D., and Rawlins, M. D. N-acetylation phenotype in bladder cancer. Hum. Toxicol., 1: 443-445, 1982.
24. Cartwright, R. Epidemiologic studies on N-acetylation and C-center ring oxidation in neoplasia. In: G. S. Omenn and H. V. Gelboin (eds.), Banbury Report 16: Genetic Variability in Responses to Chemical Exposure, pp. 359-368. Cold Spring Harbor: Cold Spring Harbor Laboratory, 1984.
25. Marcus, P. M., Vineis, P., and Rothman, N. NAT2 slow acetylation and bladder cancer risk: a meta-analysis of 22 case-control studies conducted in the general population. Pharmacogenetics, 10: 115-122, 2000.
26. Yu, M. C., Skipper, P. L., Taghizadeh, K., Tannenbaum, S. R., Chan, K. K., Henderson, B. E., and Ross, R. K. Acetylator phenotype, aminobiphenyl-hemoglobin adduct levels, and bladder cancer risk in white, black, and Asian men in Los Angeles, California. J. Natl. Cancer Inst., 86: 712-716, 1994.
27. Hein, D. W. Acetylator genotype and arylamine-induced carcinogenesis. Biochim. Biophys. Acta, 948: 37-66, 1988.
28. Vineis, P., and Pirastu, R. Aromatic amines and cancer. Cancer Causes Control, 8: 346-355, 1997.
29. Weber, W. W. The Acetylator Genes and Drug Response. New York: Oxford University Press, 1987.
30. Begg, C. B., and Zhang, Z. Statistical analysis of molecular epidemiology studies employing case-series. Cancer Epidemiol. Biomark. Prev., 3: 173-175, 1994.
31. Khoury, M. J., and Flanders, W. D. Nontraditional epidemiologic approaches in the analysis of gene-environment interaction: case-control studies with no controls! Am. J. Epidemiol., 144: 207-213, 1996.
32. Piegorsch, W. W., Weinberg, C. R., and Taylor, J. A. Non-hierarchical logistic models and case-only designs for assessing susceptibility in population-based case-controls studies. Stat. Med., 13: 153-162, 1994.
33. Umbach, D. M., and Weinberg, C. R. Designing and analysing case-control studies to exploit independence of genotype and exposure. Stat. Med., 16: 1731-1743, 1997.
34. Snedecor, G. W., and Cochran, W. G. Statistical Methods. Ames: Iowa State University Press, 1989.
35. SAS Institute Inc. SAS/STAT User's Guide. Cary, NC: SAS Institute, 1994.
36. SAS Institute Inc. SAS/STAT Software: Changes and Enhancements Through Release 6.11. Cary, NC: SAS Institute, Inc., 1996.
37. Breslow, N. E., and Day, N. E. Statistical Methods in Cancer Research. Volume 1 - The Analysis of Case-Control Studies. Lyon, France: International Agency for Research on Cancer, 1980.
38. Laird, N. M., and Mosteller, F. Some statistical methods for combining experimental results. Int. J. Technol. Assessment Health Care, 6: 5-30, 1990.
39. Whitehead, A., and Whitehead, J. A general parametric approach to the meta-analysis of randomized clinical trials. Stat. Med., 10: 1665-1677, 1991.
40. Blum, M., Demierre, A., Grant, D. M., Heim, M., and Meyer, U. A. Molecular mechanisms of slow acetylation of drugs and carcinogens in humans. Proc. Natl. Acad. Sci. USA, 88: 5237-5241, 1991.
41. Cascorbi, I., Drakoulis, N., Brockmöller, J., Maurer, A., Sperling, K., and Roots, I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am. J. Hum. Genet., 57: 581-592, 1995.
42. Graf, T., Broly, F., Hoffmann, F., Probst, M., Meyer, U. A., and Howald, H. Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers. Eur. J. Clin. Pharmacol., 43: 399-403, 1992.
43. Hickman, D., and Sim, E. N-acetyltransferase polymorphism: comparison of phenotype and genotype in humans. Biochem. Pharmacol., 42: 1007-1014, 1991.
44. Mrozikiewicz, P. M., Drakoulis, N., and Roots, I. Polymorphic arylamine N-acetyltransferase (NAT2) genes in children with insulin-dependent diabetes mellitus. Clin. Pharmacol. Ther., 56: 626-634, 1994.
45. Kleinbaum, D., Kupper, L., and Morgenstern, H. Epidemiologic Research: Principles and Quantitative Methods. New York: Van Nostrand Reinhold, 1982.
46. Vineis, P., and Ronco, G. Interindividual variation in carcinogen metabolism and bladder cancer risk. Environ. Health Perspect., 98: 95-99, 1992.
47. Begg, C. B. Publication bias. In: H. Cooper and L. V. Hedges (eds.), The Handbook of Research Synthesis, pp. 399-409. New York: Russell Sage Foundation, 1994.
48. Garcia-Closas, M., Thompson, W. D., and Robins, J. Differential misclassification and the assessment of gene-environment interactions in case-control studies. Am. J. Epidemiol., 147: 426-433, 1998.
49. Cartwright, R. A., Rogers, H. J., Barham-Hall, D., Slashan, R. W., Ahmod, R. A., Higgins, E., and Kahn, M. A. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet, 2: 842-845, 1982.
50. Vineis, P., Bartsch, H., Caparaso, N., Harrington, A. M., Kadlubar, F. F., Landi, M. T., Malaveille, C., Shields, P. G., Skipper, P., Talaska, G., and Tannenbaum, S. R. Genetically based N-acetyltransferase metabolic polymor-phism and low-level environmental exposure to carcinogens. Nature (Lond.), 369: 154-156, 1994.
51. D'Errico, A., Taoli, E., Chen, X., and Veneis, P. Genetic metabolism polymorphisms and the risk of cancer: a review of the literature. Biomarkers, 1: 149-173, 1996.
52. Kadlubar, F. F., and Badawi, A. F. Genetic susceptibility and carcinogen-DNA adduct formation in human urinary bladder carcinogenesis. Toxicol. Lett., 82: 627-632, 1995.
53. Bois, F. Y., Krowech, G., and Zeise, L. Modeling human interindividual variability in metabolism and risk: the example of 4-aminobiphenyl. Risk Anal., 15: 205-213, 1995.
54. Michaud, D., Spiegelman, D., Clinton, S., Rimm, E., Curhan, G., Willett, W., and Giovannucci, E. Fluid intake and the risk of bladder cancer in men. N. Engl. J. Med., 340: 1390-1397, 1999.
55. Yang, Q., Khoury, M. J., and Flanders, W. D. Sample size requirements in case-only designs to detect gene-environment interaction. Am. J. Epidemiol., 146: 713-720, 1997.